Group 1 - WuXi AppTec's CAR-T cell therapy, Rikeolunase injection, is expected to be included in the commercial health insurance directory, marking a significant step in China's multi-tiered medical security system [1] - The pricing for Rikeolunase injection is set at 1.29 million yuan per dose, which highlights the potential accessibility of high-cost therapies through the "commercial insurance + innovative drugs" model [1] Group 2 - Green Valley Pharmaceutical was fined 400,000 yuan for illegal promotion of its drug, Ganlutena capsules (Jiuqi Yi), which has faced efficacy controversies since its approval [2] - The fine serves as a significant warning for pharmaceutical companies, especially regarding compliance in marketing practices for new drugs with low public awareness [2] Group 3 - Libang Pharmaceutical has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, focusing on the kidney disease sector with a vertically integrated platform covering R&D, production, and commercialization [3] - The company aims to address the substantial market demand from approximately 850 million kidney disease patients globally, amidst a shortage of innovative therapies [3] Group 4 - Aidi Pharmaceutical's ADC118 tablets, a first-class new drug for HIV, have received clinical approval, representing a significant breakthrough in the development of domestic anti-HIV medications [4] - If clinical trials proceed successfully, ADC118 could disrupt the dominance of imported drugs in the HIV treatment market, providing high-quality domestic options for patients [4] Group 5 - Lepu Biopharma's MRG003 (Vibekotamab) has been approved for marketing, targeting patients with recurrent/metastatic nasopharyngeal carcinoma who have failed at least two lines of systemic chemotherapy and PD-1/PD-L1 inhibitors [5] - MRG003 is the first EGFR ADC new drug approved globally, marking a new milestone for domestic ADC development [5]